Atika Capital Management LLC Has $8.31 Million Position in Guardant Health, Inc. $GH

Atika Capital Management LLC lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 49.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 133,000 shares of the company’s stock after purchasing an additional 43,800 shares during the quarter. Atika Capital Management LLC owned 0.11% of Guardant Health worth $8,310,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in GH. TD Waterhouse Canada Inc. grew its position in Guardant Health by 3.2% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock worth $306,000 after acquiring an additional 151 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Guardant Health by 8.3% in the third quarter. PNC Financial Services Group Inc. now owns 4,016 shares of the company’s stock valued at $251,000 after purchasing an additional 307 shares during the last quarter. Main Management ETF Advisors LLC boosted its stake in shares of Guardant Health by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock valued at $1,106,000 after purchasing an additional 348 shares in the last quarter. CWM LLC boosted its stake in shares of Guardant Health by 21.6% during the third quarter. CWM LLC now owns 2,020 shares of the company’s stock valued at $126,000 after purchasing an additional 359 shares in the last quarter. Finally, Trivium Point Advisory LLC grew its holdings in shares of Guardant Health by 8.1% during the third quarter. Trivium Point Advisory LLC now owns 5,167 shares of the company’s stock worth $323,000 after purchasing an additional 385 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Guardant Health news, CTO Darya Chudova sold 5,451 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $104.04, for a total value of $567,122.04. Following the transaction, the chief technology officer directly owned 7,012 shares of the company’s stock, valued at approximately $729,528.48. The trade was a 43.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Medina Manuel Hidalgo sold 1,300 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $91.54, for a total value of $119,002.00. Following the transaction, the director owned 1,193 shares in the company, valued at $109,207.22. The trade was a 52.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 116,034 shares of company stock valued at $12,202,492. Insiders own 6.10% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GH shares. Canaccord Genuity Group raised their price objective on shares of Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, February 20th. Leerink Partners boosted their target price on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, February 20th. Evercore set a $110.00 price target on shares of Guardant Health in a research report on Friday, February 20th. Robert W. Baird initiated coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They set an “outperform” rating and a $120.00 price target for the company. Finally, Citigroup lifted their price target on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Twenty-one investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $122.57.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $88.03 on Thursday. The company’s 50 day moving average price is $104.60 and its 200-day moving average price is $89.52. Guardant Health, Inc. has a 52-week low of $36.36 and a 52-week high of $120.74. The company has a market capitalization of $11.55 billion, a P/E ratio of -26.60 and a beta of 1.67.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. The firm’s revenue for the quarter was up 39.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.62) EPS. Analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.